Meeting
2023 ASCO Annual Meeting
Phase 1 results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) or gemcitabine (gem) in advanced solid tumors.
Authors
Ryan C. Lynch
University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA
Ryan C. Lynch , Pamela N. Munster , Gerald Steven Falchook , Monika Leigh Burness , Timothy A. Yap , Geoffrey Shapiro , David R. Spigel , Manish R. Patel , Kathleen N. Moore , Dejan Juric , Susan Doleman , William D. Bradley , Thomas J. O'Shea , Judson M. Englert , Markus F. Renschler , Nina Beri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT03997968
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3099)
DOI
10.1200/JCO.2023.41.16_suppl.3099
Abstract #
3099
Poster Bd #
297
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk
Poster
2014 ASCO Annual Meeting
A phase I study to assess the safety, tolerability, and PK of dovitinib (D) in combination with gemcitabine (G) and capecitabine (C) in patients with advanced solid tumors.
First Author: Gerald J. Fetterly
Poster
2023 ASCO Annual Meeting
BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.
First Author: Manish R. Patel
Poster
2023 ASCO Annual Meeting
Phase 1/1b study of SY-5609, a selective and potent CDK7 inhibitor, in advanced solid tumors and in 2L/3L pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine +/- nab-paclitaxel.
First Author: Babar Bashir